Jasper Therapeutics (JSPR) Gains from Investment Securities (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Gains from Investment Securities of -$6.4 million for Q4 2025, down 206.29% quarter-over-quarter from -$2.1 million in Q3 2025.
Jasper Therapeutics (JSPR) Gains from Investment Securities (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$6.4 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$6.4 million; the TTM figure through Dec 2025 stood at -$8.5 million (changed N/A YoY), while the FY2025 annual figure was -$8.5 million, down 1318.29% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$6.4 million, down from -$2.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $575000.0 in Q1 2023, with the low at -$6.4 million in Q4 2025.
- The 4-year median for Gains from Investment Securities is -$500000.0 (2022), against an average of -$1.9 million.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities plunged 200.0% in 2022, then soared 109.5% in 2023.
- Jasper Therapeutics' Gains from Investment Securities stood at -$50000.0 in 2021, then slumped by 200.0% to -$150000.0 in 2022, then soared by 483.33% to $575000.0 in 2023, then slumped by 1218.09% to -$6.4 million in 2025.
- Business Quant data shows JSPR's Gains from Investment Securities at -$6.4 million in Q4 2025, -$2.1 million in Q3 2025, and $575000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.43 Mn |
| Dec 31, 2025 | -6.43 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Mar 31, 2023 | 575,000.00 |
| Mar 31, 2023 | 575,000.00 |
| Dec 31, 2022 | -150,000.00 |
| Dec 31, 2022 | -150,000.00 |
| Sep 30, 2022 | -155,000.00 |
| Sep 30, 2022 | -155,000.00 |
| Jun 30, 2022 | -845,000.00 |
| Jun 30, 2022 | -845,000.00 |
| Mar 31, 2022 | -6.05 Mn |
| Mar 31, 2022 | -6.05 Mn |
| Dec 31, 2021 | -50,000.00 |
| Dec 31, 2021 | -50,000.00 |
| Dec 31, 2020 | 9.31 Mn |
| Dec 31, 2020 | 9.31 Mn |
| Sep 30, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.66 Mn |